Asia-Pacific Molecular Diagnostics Market Poised for $11.87 Billion by 2030

Molecular Diagnostics in Asia-Pacific Poised for $11.87 Billion Market by 2030

Asia-Pacific Molecular Diagnostics Market - 2023-2030 Meticulous Research a leading market research company, published a research report titled, Asia-Pacific Molecular Diagnostics Market by Product & Service (Kits, Instruments) Test Type (Lab, PoC) Technology (PCR, ISH, Sequencing, INAAT, Microarray) Application (Infectious Diseases, Oncology) End User (Hospitals, Diagnostic Lab) - Forecast to 2030 . Download Free Sample Report@ https://www.meticulousresearch.com/download-sample- report/cp_id=5719?utm_source=pdf&utm_medium=social&utm_campaign=product&utm_co ntent=10-09-2024 According to the latest release by Meticulous Research , the Asia-Pacific molecular diagnostics market is projected to reach a valuation of $11.87 billion by 2030, growing at a compound annual growth rate (CAGR) of 7.2% from 2023 to 2030. This market growth is primarily driven by increasing healthcare expenditure, the rising use of Point of Care (PoC) diagnostic tests, continuous advancements in molecular diagnostics technology, and increased funding for Research and Development (R&D) in molecular diagnostics products. Additionally, the growing focus on companion diagnostics is expected to provide significant growth opportunities for the market. However, challenges such as stringent regulatory frameworks, high costs of molecular diagnostic tests, and a shortage of skilled professionals may hinder market growth. Key Players: The key companies in the Asia-Pacific molecular diagnostics market include: F. Hoffmann-La Roche Ltd (Switzerland)Hologic, Inc. (U.S.)QIAGEN N.V. (Netherlands)Danaher Corporation (U.S.)bioM rieux S.A. (France)Becton, Dickinson and Company (BD) (U.S.)Siemens Healthineers AG (Germany)Dia Sorin S.p.A. (Italy)Abbott Laboratories (U.S.)Thermos Fisher Scientific Inc. (U.S.)Agilent Technologies, Inc. (U.S.)Illumina, Inc. (U.S.)Seegene, Inc. (South Korea) Future Outlook: The Asia-Pacific molecular diagnostics market is segmented based on Product & Service (Kits & Reagents, Instruments, Software & Services), Test Type (Laboratory Tests, Point of Care (PoC) Tests), Technology (Polymerase Chain Reaction (PCR), In Situ Hybridization (ISH), Isothermal Nucleic Acid Amplification Technology (INAAT), Microarrays, Sequencing, Mass Spectrometry, Other Technologies), Application (Infectious Diseases, Oncology, Genetic Testing, Neurological Diseases, Cardiovascular Diseases, Other Applications), and End User (Hospitals & Clinics, Diagnostic Laboratories, Academic & Research Institutes, Other End Users). The report also includes a detailed analysis of industry competitors and examines the market at the country level. Product & Service Segment: In 2023, the kits & reagents segment is expected to dominate the market due to the frequent use of diagnostic kits, the availability of a wide range of disease-specific kits for early diagnosis of chronic and infectious diseases, and technological advancements in molecular diagnostics. Test Type Segment: Laboratory tests are projected to hold the largest share in 2023, driven by increased lab testing, widespread availability in hospitals, laboratories, and academic & research institutes, and higher accuracy and reliability of lab tests. Page 1 of 2 Meticulous Research| sales@meticulousresearch.com

Asia-Pacific Molecular Diagnostics Market - 2023-2030 Technology Segment: The polymerase chain reaction (PCR) segment is anticipated to lead the market in 2023 due to its ability to rapidly amplify specific DNA segments and its high sensitivity, making it effective for detecting low-number targets. The high demand for PCR devices further supports this segment's dominance. Application Segment: Infectious diseases are expected to account for the largest share of the market in 2023, attributed to the rising incidence of infectious diseases and increased efforts by government organizations for early diagnosis. End User Segment: Hospitals & clinics are expected to hold the largest share of the market in 2023, as these institutions conduct a wide range of tests to diagnose various medical conditions, ensuring proper clinical planning for treatment and prevention. Buy Now@ https://www.meticulousresearch.com/Checkout/39502056?utm_source=pdf&utm_medium=soc ial&utm_campaign=product&utm_content=10-09-2024 About Meticulous Research : Meticulous Research was founded in 2010 and incorporated as Meticulous Market Research Pvt. Ltd. in 2013 as a private limited company under the Companies Act, 1956. Since its incorporation, the company has become the leading provider of premium market intelligence in North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. The name of our company defines our services, strengths, and values. Since the inception, we have only thrived to research, analyze, and present the critical market data with great attention to details. With the meticulous primary and secondary research techniques, we have built strong capabilities in data collection, interpretation, and analysis of data including qualitative and quantitative research with the finest team of analysts. We design our meticulously analyzed intelligent and value-driven syndicate market research reports, custom studies, quick turnaround research, and consulting solutions to address business challenges of sustainable growth. Contact Us: Meticulous Research Email- sales@meticulousresearch.com Contact Sales- +1-646-781-8004 Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research Page 2 of 2 Meticulous Research| sales@meticulousresearch.com